home All News open_in_new Full Article

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

SAN DIEGO — Invivoscribe is proud to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM), LLC has received approval from the New York State Department of Health to offer the FLT3 ITD MRD Assay to assess measurable residual disease (MRD). LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides […]


today 2 w. ago attach_file Other

attach_file Politics
attach_file Society
attach_file Politics
attach_file Economics
attach_file Other
attach_file Science
attach_file Other
attach_file Society
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Culture
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Sport
attach_file Society
attach_file Culture


ID: 3181309358
Add Watch Country

arrow_drop_down